The effect of Hyaluronidaz and Ozon on spinal canal stenosis

Phase 3

Recruiting

• Conditions: umbosacral spinal stenosis.; Spinal stenosis, lumbar region; M48.06

• Registration Number: IRCT20191004044980N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 December 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Back pain and other symptoms of spinal canal stenosis in the last six months
Age between 35_75 years
Confirmation of spinal canal stenosis through MRI and EDX

Exclusion Criteria

Diabetes Melitus
Rheumatologic and collagen vascular diseases
peripheral neuropathy and nerve injury
Brucellosis
BMI more than 41
History of trauma and spinal fracture
Bleeding disorder
Allergic reaction to Bovin protein
Genetic disease such as Galactose intolerance or Lactase deficiency
Patient with cardiac problem
Inability to communicate and complete the questionnaire
History of liver ,kidney and cardiopulmonary problem
History of periarticular or intraarticular in the past 6 months
Pregnant women
People with cancer
People taking Anticoagulant
Favism

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain score according to Visual Analog Scale. Timepoint: At baseline (before intervention), 2, 4 and 8 weeks after injection. Method of measurement: Visual Analog Scale.;Patient Performance Score in Oswestry Disability Scale. Timepoint: At baseline (before intervention), 2, 4 and 8 weeks after injection. Method of measurement: Oswestry Low Back Pain Questionnaire.;Patient Performance Score in QUEBEC Back Pain Disability. Timepoint: At baseline (before intervention), 2, 4 and 8 weeks after injection. Method of measurement: QUEBEC Back Pain Disability Qestionnaire.